Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Wyeth loratadine deal

This article was originally published in The Tan Sheet

Executive Summary

Impax Labs to supply Wyeth Consumer Healthcare with generic OTC forms of Schering-Plough's Claritin-D 12-hour, 24-hour extended release tablets, Hayward, Calif.-based firm reports June 20. "Semi-exclusive" worldwide agreement allows Impax to license products to companies other than Wyeth, demands up-front milestone payments. Deal appears to cover loratadine forms other than those sought in Wyeth's 505(b)(2) application submitted to FDA early this year (1"The Tan Sheet" Feb. 4, 2002, p. 3)...

You may also be interested in...

Claritin Patent Infringement Suit Brings Industry Into OTC Antihistamine Fray

Schering-Plough's lawsuits against McNeil Consumer Healthcare and Whitehall-Robins could at least temporarily relieve FDA of having to make a highly charged public policy decision on whether to advocate a forced switch of second-generation antihistamines

The ICER Process: Allergan Engagement Improves Cost Effectiveness Rating For Ubrelvy

ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.

US FDA’s 2020 Approvals: A Deep Pipeline, And More Of The Expected

Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts